Weekly Investment Analysts’ Ratings Changes for Alnylam Pharmaceuticals (ALNY)

Several analysts have recently updated their ratings and price targets for Alnylam Pharmaceuticals (NASDAQ: ALNY):

• 3/25/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by Chardan Capital. They now have a $425.00 price target on the stock.
• 3/25/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $510.00 price target on the stock.
• 3/21/2026 – Alnylam Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/16/2026 – Alnylam Pharmaceuticals had its “hold” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $330.00 price target on the stock, down from $522.00.
• 2/18/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $510.00 price target on the stock.
• 2/17/2026 – Alnylam Pharmaceuticals was upgraded by Freedom Capital from “hold” to “strong-buy”.
• 2/17/2026 – Alnylam Pharmaceuticals had its price target raised by Canaccord Genuity Group Inc. from $415.00 to $429.00. They now have a “buy” rating on the stock.
• 2/14/2026 – Alnylam Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 2/13/2026 – Alnylam Pharmaceuticals had its price target lowered by Chardan Capital from $475.00 to $425.00. They now have a “buy” rating on the stock.
• 2/12/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by Bank of America Corporation.
• 2/12/2026 – Alnylam Pharmaceuticals had its price target lowered by Needham & Company LLC from $529.00 to $510.00. They now have a “buy” rating on the stock.
• 1/30/2026 – Alnylam Pharmaceuticals had its price target lowered by Morgan Stanley from $495.00 to $408.00. They now have an “equal weight” rating on the stock.
• 1/30/2026 – Alnylam Pharmaceuticals had its price target lowered by HC Wainwright from $570.00 to $510.00. They now have a “buy” rating on the stock.
• 1/30/2026 – Alnylam Pharmaceuticals had its price target lowered by Bank of America Corporation from $529.00 to $462.00. They now have a “buy” rating on the stock.
• 1/28/2026 – Alnylam Pharmaceuticals is now covered by Barclays PLC. They set an “overweight” rating and a $527.00 price target on the stock.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Pushkal Garg sold 1,775 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $319.74, for a total value of $567,538.50. Following the transaction, the executive vice president directly owned 23,406 shares in the company, valued at $7,483,834.44. This trade represents a 7.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total transaction of $528,193.96. Following the completion of the sale, the executive vice president directly owned 21,860 shares of the company’s stock, valued at approximately $6,989,297.80. The trade was a 7.03% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 53,923 shares of company stock valued at $18,072,087. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.